ANGO · Angiodynamics Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| backlog | $0.3M | year ended May 31, 2026 filing | — |
| Sales outside the U.S. as a percentage of net sales | 14% | fiscal year ended May 31, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANGO
this stock
Angiodynamics Inc
|
$627.84M | +17.7% | +10.2% | — | 3.2% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -30.8% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -15.2% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -9.1% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANGO | -2.5% | -2.3% | +47.6% | -1.8% | +17.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -2.2% | -1.9% | +35.4% | -2.7% | +4.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.